FDA approves first and only treatment for leading cause of blindness

Apellis Pharmaceuticals' Syfovre, a treatment for geographic atrophy, has received FDA approval. 

It is the first and only treatment that has been approved for geographic atrophy, a leading cause of blindness, according to a Feb. 17 news release. 

Syfovre is set to be available to specialty distributors and pharmacies across the country in March.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast